.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,723,289

« Back to Dashboard

Details for Patent: 5,723,289

Title: Parallel selex
Abstract:This invention discloses a method for coevolving products from two or more reactants, along with the nucleic acid that can facilitate the reaction for making the products. The invention further discloses the products and facilitating nucleic acids produced by said method.
Inventor(s): Eaton; Bruce E. (Boulder, CO), Gold; Larry (Boulder, CO)
Assignee: NeXstar Pharmaceuticals, Inc. (Boulder, CO)
Filing Date:Sep 20, 1994
Application Number:08/309,245
Claims:1. A method for producing a product that binds to a target comprising:

(a) preparing a nucleic acid test mixture;

(b) coupling each member of said nucleic acid test mixture with a first reactant comprised of a small organic molecule with a molecular weight in the range of 2 to 1000 to form a nucleic acid-first reactant test mixture;

(c) forming a product library by contacting said nucleic acid-first reactant test mixture with a mixture of free reactants comprised of small organic molecules with a molecular weight in the range of 2 to 1000, wherein said product library is formed as a result of a bond formation reaction between said first reactant and at least one of said free reactants, wherein said bond formation reaction is selected from the group consisting of a condensation reaction, a hydrolysis reaction, a cycloaddition reaction, a conjugate addition reaction, an aldol condensation reaction, a cyclopropanation reaction, a hydrogenation reaction, and a cyclotrimerization reaction, wherein said bond formation reaction is facilitated by the nucleic acid coupled to said first reactant;

(d) contacting the product library of step (c) with a target, wherein products having an increased binding affinity to said target relative to the product library may be partitioned from the remainder of the product library; and

(e) partitioning said products having said increased binding affinity to said target from the remainder of the product library, whereby products that bind to said target are produced.

2. A method for coproducing nucleic acids that facilitate bond formation between a first and a free reactant and products that bind to a target comprising:

(a) preparing a nucleic acid test mixture;

(b) coupling a first reactant comprised of a small organic molecule with a molecular weight in the range of 2 to 1000 to each member of said nucleic acid test mixture to form a nucleic acid-first reactant test mixture;

(c) forming a product library by contacting said nucleic acid-first reactant test mixture with a mixture of free reactants comprised of small organic molecules with a molecular weight in the range of 2 to 1000, wherein bond formation between a first reactant and a free reactant is facilitated by the nucleic acid which is coupled to said first reactant whereby each product is coupled to a nucleic acid;

(d) contacting said product library with a target, wherein products having an increased binding affinity to said target relative to the product library may be partitioned from the remainder of the product library;

(e) partitioning said products having said increased binding affinity to said target from the remainder of the product library, whereby said products are produced; and

(f) amplifying the nucleic acid coupled to each product having an increased binding affinity to said target, to yield a mixture of nucleic acids that facilitate bond formation, whereby said nucleic acids that facilitated bond formation a first and a free reactant are coproduced.

3. The method of claim 3 which further comprises:

(g) coupling the amplified nucleic acids with said first reactant;

(h) repeating steps (c) through (g) until the product having said increased binding affinity to said target is produced in sufficient quantity for structure determination.

4. A method for producing a product comprising contacting a first reactant with a free reactant, each reactant comprised of a small organic molecule with a molecular weight in the range of 2 to 1000 wherein a bond formation reaction selected from the group consisting of a condensation reaction, a hydrolysis reaction, a cycloaddition reaction, a conjugate addition reaction, an aldol condensation reaction, a cyclopropanation reaction, a hydrogenation reaction, and a cyclotrimerization reaction that is facilitated by a nucleic acid coupled to first reactant occurs between said first reactant and said free reactant, whereby said product is produced.

5. The method of claim 1 wherein said nucleic acid test mixture comprises nucleic acids having a region of conserved sequences and a region of randomized sequences.

6. The method of claim 1 wherein said nucleic acid coupled to said first reactant is selected from the group consisting of single-stranded RNA, single-stranded DNA and double-stranded DNA.

7. The method of claim 1 wherein said nucleic acid test mixture comprises pyrimidines modified at the 2'- or 5-positions.

8. The method of claim 1 wherein said nucleic acid test mixture comprises purines modified at the 8-position.

9. The method of claim 1 which further comprises a linker group coupled between said first reactant and said nucleic acid.

10. The method of claim 9 wherein said linker group has a size in the range of 10 to 1000 .ANG..

11. The method of claim 10 wherein said linker group is selected from the group consisting of PEG, polyvinyl alcohol, polyacrylates and polypeptides.

12. The method of claim 1 wherein said first reactant is a dienophile, said free reactant is a diene, and said product is a cyclohexene.

13. The method of claim 2 wherein said nucleic acid test mixture comprises nucleic acids having a region of conserved sequences and a region of randomized sequences.

14. The method of claim 2 wherein said nucleic acid coupled to said first reactant is selected from the group consisting of single-stranded RNA, single-stranded DNA and double-stranded DNA.

15. The method of claim 3 wherein said nucleic acid test mixture comprises pyrimidines modified at the 2'- or 5-positions.

16. The method of claim 2 wherein said nucleic acid test mixture comprises purines modified at the 8-position.

17. The method of claim 2 which further comprises a linker group coupled between said first reactant and said nucleic acid.

18. The method of claim 17 wherein said linker group has a size in the range of 10 to 1000 .ANG..

19. The method of claim 18 wherein said linker group is selected from the group consisting of PEG, polyvinyl alcohol, polyacrylates and polypeptides.

20. The method of claim 3 wherein said first reactant is a dienophile, said free reactant is a diene, and said product is a cyclohexene.

21. The method of claim 4 wherein said nucleic acid is selected from the group consisting of single-stranded RNA, single-stranded DNA and double-stranded DNA.

22. The method of claim 4 wherein said nucleic acid comprises pyrimidines modified at the 2'- or 5-positions.

23. The method of claim 4 wherein said nucleic acid comprises purines modified at the 8-position.

24. The method of claim 4 wherein said nucleic acid is coupled to said first reactant.

25. The method of claim 24 which further comprises a linker group coupled between said first reactant and said nucleic acid.

26. The method of claim 25 wherein said linker group has a size in the range of 10 to 1000 .ANG..

27. The method of claim 26 wherein said linker group is selected from the group consisting of PEG, polyvinyl alcohol, polyacrylates and polypeptides.

28. The method of claim 4 wherein said first reactant is a dienophile, said free reactant is a diene, and said product is a cyclohexene.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc